Saltar directamente a búsqueda Saltar directamente a índice A-Z Saltar directamente a navegación Saltar directamente al contenido del sitio Saltar directamente a las opciones de páginas
Inicio
Compartir
Compartir

Selected Publications on Influenza Vaccine Effectiveness

Ahmed AH, Nicholson KG, Nguyen-van Tam JS, et al. Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic. Epidemiol Infect 1997; 118:27-33.

Arden NH, Patriarca PA, and Kendal AP. Options for the Control of Influenza: Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. UCLA Symposia on Molecular and Cellular Biology 1985; 36: 155-168. Print.

Ashkenazi S, Vertruyen A, Arístegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25(10):870-9.

Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States. Am. J Public Health 1986; 76:761-5.

Barker WH, Mullooly JP. Influenza vaccination of elderly persons: reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980; 244(22): 2547-9.

Baxter, Roger et al. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vacuna 2010; 28: 7267-7272.

Belshe RB, Mendelman PM, Treanor, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med. 1998; 338(20):1405-12.

Belshe RB, Gruber WC. Prevención de la otitis media en niños con la vacuna intranasal contra la influenza atenuada en virus vivos. Pediatr Infect Dis J. 2000; 19(5 Suppl):S66-71.

Belshe RB, Edwards KM, Vesikari T, et al. Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96.

Beran J, Vesikari T, Wertzova V, et al. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis 2009; 200(12):1861-9.

Bragstad K, Emborg HD, Fischer TK, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13-A rapid epidemiological and virological assessment. Eurosurveillance 2013; 18(6).

Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284(13):1655-63.

Castilla J, Martinez-Baz I, Martinez-Artola V, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, Season 2011/12. Eurosurveillance 2013; 18(5).

Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106:973.

Coleman MS, Fontainesi J, Meltzer MI, et al. Estimating medical practice expenses from administering adult influenza vaccinations. Vaccine 2005; 23(7):915-23.

Dayan GH, Nguyen VH, Debbag R, et al. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vacuna 2001; 19: 4204-13.

De Villiers P, Steel D, Hiemstra L, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vacuna 2010; 28: 228-234.

Edmondson W.P., Rothenberg R, White P.W. et al. A Comparison of Subcutaneous, Nasal, and Combined Influenza Vaccination. II. Protection Against Natural Challenge. American Journal of Epidemiology 1971; 93(6):481-486.

Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270:1956-61.

Fireman, Bruce et al. “Influenza Vaccination and Mortality: Differentiating Vaccine Effects from Bias.” Am J Epidemiol.2009; 170:650-656.

Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006; 25(10):860-9.

Fleming DH, Watson JM, Nicholas S, et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989-90 using a general practice database. Epidemiol Infect 1995; 115:581-9.

Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136:296-307.

Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. La eficacia de la vacunación contra la influenza en los ancianos. Un ensayo aleatorio de administración controlada de placebo sometido a una revisión por pares de forma anónima. JAMA1994; 272(21):1661-5.

Gross PA, Hermogenese AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature. Ann Intern Med. 1995;123(7):518-27.

Gross PA, Quinnan GV, Rodstein M, et al. Association of influenza immunization with reduction in mortality in an elderly population. A prospective study. Arch Intern Med. 1988; 148(3): 562-5.

Gurfinkel EP, de la Fuente RL. Two-year follow-up of the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Registry. Tex Heart Inst J. 2004; 31(1):28-32.

Hak E, Buskens E, Van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: The PRISMA study. Arch Intern Med 2005; 165:274-80.

Hak E, Verheij TJ, Grobbee DE, et al. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health 2002; 56:951-5.

Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20(7-8):1240-1247.

Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomized controlled trial. BMJ 2006; 333(7581):1241.

Herrera GA, Iwane MK, Cortese M, et al. Influenza vaccine effectiveness among 50-64-year-old persons during a season of poor antigenic match between vaccine and circulating influenza virus strains: Colorado, United States, 2003-2004. Vacuna 2007; 25: 54-60.

Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003; 290(12):1608-16.

Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Wkly Epidemiol Rc 2008; 83:359-64.

Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006; 35:337-44.

Jackson ML, Nelson JC, Weiss NS, et al. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet 2008; 372:398-405.

Jackson LA, Gaglani MJ, Keyserling HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010; 10:71.

Janjua, N.Z. Estimates of influenza vaccine effectiveness for 2007-2008 From Canada's Sentinel Surveillance System: Cross-Protection Against Major and Minor Variants. JID 2012: 1858-1868.

Keren R, Zaoutis TE, Saddlemire S, et al. Direct medical cost of influenza-related hospitalizations in children. Pediatrics 2006; 118:1321--7.

Kissling E et al. “I-Move towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-center case-control study in Europe, 2008-9.” Euro Surveill.2009; 14(44):1-7.

Kissling E. et al. "I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe. PLos One 2011; 6(11): 1-11.

Kissling E. et al. Low and decreasing vaccine effectiveness against Influenza A (H3) in 2011-12 among vaccination target groups in Europe: Results from the I-Move Multicentre Case-Control Study. Euro Surveill 2013; 18(5).

Lang PO, Mendes A, Socquet J et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clinical Interventions In Aging 2012; 7:55-64.

Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108:e24.

Macintosh V, Tastad k, Eick-Cost A. Mid-season influenza vaccine effectiveness 2011-2012: A Department of Defense global, Laboratory-based, Influenza Surveillance System case-control study estimate. Vaccine 2013; SO264-410X.

Maciosek MV, Solberg LI, Coffield AB, et al. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 2006; 31:72--9.

McMenamim J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-influenza infection in primary care in the United Kingdom: Mid-Season analysis 2012/13. Eurosurveillance 2013; 18(5).

Meltzer MI, Neuzil KM, Griffin MR, et al. An economic analysis of annual influenza vaccination of children. Vacuna 2005; 23: 1004-14.

Molinari NA, Ortego Sanchez IR, Messonier M, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007; 25(27):5086-5096.

Monto AS, Hornbuckle K, Ohmit SE. La efectividad de la vacuna contra la influenza en ancianos residentes de asilos: un estudio de cohorte. Am J Epidemiol. 2001; 154(2):155-60.

Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009; 361(13):1260-7.

Morbidity and Mortality Weekly Report (MMWR). Early Estimates of Seasonal Influenza Vaccine Effectiveness-United States, January 2013. Weekly January 18, 2013; 62(02):32-35.

Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-52.

Naghavi M, Barlas Z, Siadaty S, et al. Association of Influenza Vaccination and Reduced Risk of Recurrent Myocardial Infarction. Journal of the American Heart Association.2000; 102:3039-3045.

Neuzil KM, Dupont WD, Wright PF, Edwards KM. Eficacia de las vacunas inactiva y de virus adaptados al frío contra la influenza de tipo A, 1985 a1990: la experiencia pediátrica. Pediatr Infect Dis J. 2001; 20(8):733-40.

Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161:749-59.

Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397-403.

Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vacuna 2003; 21: 2207-17.

Nichol KL, Margolis J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis. 2001; 184:665-70.

Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999; 282(2):137-44

Nichol KL, Nordin JD, Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:1373-81.

Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med. 1998; 158:1769-76.

Nordin J, Mullooly J, Poblese S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis 2001; 184:665-70.

Ohmit S, Petrie J, Malosh R, et al. Influenza vaccine effectivenss in the community and the household. Clin Infect Dis. 2013; 10.1093/cid/cit060.

Oshitani H, Saito R, Seki N et al. Influenza Vaccination Levels and Influenza-Like Illness in Long-Term-Care Facilities for Elderly People in Niigata, Japan, During an Influenza A (H3N2) Epidemic. Infection Control and Hospital Epidemiology 2000; 21(11):728-730.

Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(1):36-44.

Pebody RG, Andrews N, Mcmenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: Evidence of waning intra-seasonal protection. Eurosurveillance 2013; 18(5).

Petrie JG, Ohmit SE, Johnson E, et al. Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine Failures. JID. 2011; 203(9):1309-1315.

Phrommintikul A, Kuanprasert S, Wongcharoen W,et al. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011; 32(14):1730-5.

Prosser, L.A. (2012, May 16). Cost-effectiveness of influenza vaccine. Retrieved from the National Influenza Vaccine Summit Website.

Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006; 12:1548--58.

Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain: a test-negative, hospital-based, case-control study. Vacuna 2010; 28: 7460-7.

Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine 2009; 27(7):1101-10.

Rivetta D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev 2006; (3):CD004876.

Sander B, Kwong JC, Bauch CT, et al. Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 2010; 7:1000256.

Saxen H, Virtanen M. Estudio aleatorio doble ciego, controlado con placebo sobre la eficacia de la vacuna contra la influenza y el ausentismo de trabajadores de la salud. Pediatr Infect Dis J. 1999; 18:779-83.

Scheifele DW, Bjornson G and Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. Canadian Medical Association Journal 1990; 142 (2): p. 127-130.

Skowronski Dm, Janjua NZ, Serres GD, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's Sentinel Surveillance Network, January 2013. Eurosurveillance 2013; 18(5).

Talbot HK, Griffin, MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J. Infect Dis 2011; 203:500-8.

Thijs, C. Mortality benefits of influenza vaccination in elderly people. The Lancet, 460-461.

Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly (Review). The Cochrane Library 2010; 9.

Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999; 18(9-10):899-906.

Treanor, John J. et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. CID 2012; 55(7):951-959.

Treanor John and Szilagyi Peter. Influenza Vaccine-Glass Half Full or Half Empty? Clin Infect Dis. 2013; doi: 10.1093/cid/cit064.

Vu T, Farish S, Jenkins M, et al. A Meta-analysis of effectiveness of influenza vaccine in person aged 65 years and over living in the community. Vacuna 2002; 20: 1831-6.

Weingarten S, Staniloff H, Ault M, et al. Do hospital employees benefit from the influenza vaccine? A placebo-controlled clinical trial. J Gen Intern Med 1988; 3:32-7.

White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999; 103:e73.

Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA. 1999; 281:908-13.

 

Contáctenos:
  • Centros para el Control y la Prevención de Enfermedades
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contacte CDC-INFO

 

Descargo de responsabilidad: Es posible que en este sitio encuentre algunos enlaces que le lleven a contenido disponible sólo en inglés. Además, el contenido que se ha traducido del inglés se actualiza a menudo, lo cual puede causar la aparición temporal de algunas partes en ese idioma hasta que se termine de traducir (generalmente en 24 horas). Llame al 1-800-CDC-INFO si tiene preguntas sobre la influenza de temporada, cuyas respuestas no ha encontrado en este sitio. Agradecemos su paciencia.

  • Última modificación de la página 21 de febrero de 2013
  • Última actualización de la página: 21 de febrero de 2013
USA.gov: el portal oficial en Internet del gobierno de los EE.UU.Departamento de Salud y Servicios Humanos
Centros para el Control y la Prevención de Enfermedades, 1600 Clifton Rd. Atlanta, GA 30333, EE. UU.
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Comuníquese con CDC-INFO